Subscribe to Newsletter

Retina

Business & Profession Retina

Heads Up!

| Mark Hillen

A head-mounted iPhone-based ophthalmoscope is the latest step in the rapidly evolving world of smartphone fundoscopy

Subspecialties Retina

Benchmarking Stargardt Disease

| Mark Hillen

What does analysis of the last five years of the literature on Stargardt Disease tell us about the priorities of the field and the major contributors to it?

Subspecialties Professional Development

First Lady of the Gonin Medal

Sitting Down With Alice McPherson,founder of the Retina Research Foundation

Subspecialties Retina

Benchmarking DME

| Mark Hillen

What does analysis of the last five years of literature on diabetic macular edema tell us about the priorities of the field and the major contributors to it?

Subspecialties Retina

Interleukin for a better wet AMD therapy

| Mark Hillen

Subcutaneously-administrated IL-18 works well to reverse choroidal neovascularization (in mice).

Subspecialties Retina

The Vitreomacular Interface Influences AMD Outcomes

| Isabelle Leach

Evidence is stacking up that the configuration of the VMI alters the functional and anatomic efficacy of anti-VEGF drugs.

Subspecialties Retina

Combining Laser and Anti-VEGF for the Treatment of DME

| Stela Vujosevic

Advances in understanding of the therapeutic mechanisms that underpin micropulse laser treatment suggest that protocols for treatment of diabetic macular edema should be integrated.

Business & Profession Cataract

A Vision Timebomb

| Mark Hillen

Although baby boomers may be in a state of denial regarding their own aging, ophthalmologists know differently. In particular, four diseases of the ageing eye comprise a demographic and economic timebomb.

Subspecialties Retina

Aspirin not Linked to AMD

| Mark Hillen

Previous studies linked aspirin use with age-related macular degeneration, but new data suggest otherwise: aspirin is innocent of all charges.

Subspecialties Retina

Statins Protect Elderly Against Macular Degeneration

| Mark Hillen

If you’re aged over 68 years, then statins significantly reduce your risk of developing AMD; it has no impact on younger age groups.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: